At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 215 enrolled
Drug / intervention
Enzalutamidedrug
Likely dose
Enzalutamide 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate
In Brief
A Phase 4 clinical trial evaluating Enzalutamide for Metastatic Castration-Resistant Prostate Cancer. Completed, enrolled 215 participants across 50 sites in 5 countries.
Detailed Summary
The objective of this study was to evaluate the efficacy and safety of enzalutamide treatment in patients with progressive metastatic castration-resistant prostate cancer previously treated with abiraterone acetate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, Germany, Spain, United Kingdom
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2014
Primary CompletionMay 2016
Study CompletionSep 2017
TodayJul 2026
First PostedApr 17, 2014
Enrollment StartMay 23, 2014
Primary CompletionMay 8, 2016
Study CompletionSep 29, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.2 years ago
Interventions
Enzalutamidedrug
Participants received 160 mg of enzalutamide (soft capsules) orally once daily.